The increasing drug prices in Europe

Vytenis Andriukaitis

Vytenis Andriukaitis, Member of the EC in charge of Health and Food Safety, and Carlos Moedas, Member of the EC in charge of Research, Science and Innovation, awarded the “Horizon Prize – Better Use of Antibiotics” and “The EU Health Awards for NGO’s fighting Antimicrobial Resistance” at a ceremony hold in Leuven. © European Union , 2017 / Source: EC – Audiovisual Service / Photo: Lukasz Kobus.

This article was written by one of our passionate readers, Mrs Rachel Everly. The opinions expressed within reflect only the writer’s views and not The European Sting’s position on the issue.

Rising drug prices have not been a recent issue, it has always been a part and parcel of the medical expenses. Not only is the United States suffering through a spike in the prices of medicines, but European medical bills have taken a toll for the worse as well. Prior to that, Europe had refrained from huge raises in the prices and until 2011, the selling price of many prescription pills had been steadily low.

Since most of the European nations are funding the healthcare systems on a government level, it is only understandable that they would want to keep a close track of the pharmaceutical industry. Due to this reason, the European Pharmaceutical companies are known to work on laws and regulations that restrict them from increasing the prices of the medicines for more than once a year. The price, profits, and comparison of the prices with the international market were always screened and assessed throughout the year without adjusting the prices.

In 2011, many European countries saw a gradual rise in multiple medicines and the rates have been rising ever since, without any restriction. This will affect many consumers and the fee structure of their individual health plans. To counter this problem, European Parliament’s environment Committee (ENVI) is favoring a non-legislative proposition that will strive for making these products more widespread in the European region. However, this must not be confused with an actual law being added in the region’s policies, as it is merely a resolution waiting to be approved by the authorities. With time, it may be considered and the European Union may only then choose to implement it.

The price of specific drugs has been a matter of huge concern for the public. Looking at the prices of those medicines in the previous years has shown an increase in prices for as much as over 1000%. Drugs that are used for leukemia patients have an increased price of 1225%, while tamoxifen, which is used primarily for breast cancer has risen by 1080% from 2011 to 2016. A chemotherapy drug has seen a spike of 1500% but later was fined for 5 million euros for an illegal increase in the price.

Charges of relatively new drugs that have little to no competition are also in the race for increasing their prices up to stupendous amounts. Multiple Sclerosis and Cancer treatment drugs are hiking due to lack of competition and insurance companies and pharmacy beneficiaries are losing against keeping these companies at bay.

The setting not only destabilizes the people who are insured but deeply affects the people who chose not to be insured or cannot afford healthcare. Previously, a person who could not have afforded to have themselves operated could find comfort in medicines. The same is not the case anymore and medical prescription drugs have become even more unattainable than before for many uninsured people out there. Seniors who have retired and do not have an insurance plan can also be looking at paying higher prices than they have previously been paying.

It has been debated for more than one year that the prices of the drugs do not represent the true cost of its production. It is concluded that the price of its manufacturing is far lower than the price label put on the product.  Most of these increments in prices have more to do with profits for these drug manufacturing companies and little to do with the increasing demands and lack of supply. To counter any research and development aspect of a new drug and decrease its cost, the patient-driven research is promoted. This means that the patient can sponsor the research and have the cure developed and tested.

Another speculation that has also been made is that due to the fact that they are only allowed to raise the costs once a year. This has made the marketers overly cautious and in order to withstand any possible demand and supply problem, or a price hike in the global market, they increase their rates by a huge percentage.

In order to provide a safer and more affordable plan for the healthcare system, the government, the people, and the drug manufacturers must work together. More and more efforts have been put on by EU health ministers in 2016 to warn the pharmaceuticals to lower the prices down as it has created a market that is highly unapproachable.

Join the Hive!

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

What’s the latest on coronavirus antibody tests?

Remembering Kofi Annan

Female leaders warn about the erosion of women’s rights

Yemen: Escalation in fighting must stop ‘before it’s too late’, Griffiths tells Security Council

Romania: MEPs are deeply concerned about judicial independence and rule of law

Zuckerberg, a paella, and the mighty EU questionnaires that would stop Whatsapp acquisition by Facebook?

UN cultural agency removes birthplace of Jesus from its list of heritage sites in danger

How the massive plan to deliver the COVID-19 vaccine could make history – and leverage blockchain like never before

EU tourism industry expects a new record year in 2014

Youth leaders share positive visions of the future, as Guterres launches UN75 in New York

Apple Vs. EU: Will the US tech giant ever pay for taking advantage of Ireland’s taxation?

COVID-19 lessons learned: stronger role for EU medicines regulator

Mergers: Commission prohibits Siemens’ proposed acquisition of Alstom

A Sting Exclusive: “There can be no global deal on emissions without China and the USA”, Conservative MEP Ian Duncan stresses from Brussels

UN forum spotlights cities, where struggle for sustainability ‘will be won or lost’

This is the state of the world’s health, in numbers

Peru is building a new international airport near Machu Picchu – and archaeologists are worried

The new ethical dilemmas in medicine of the 21st century

Commission extends transparency and authorisation mechanism for exports of COVID-19 vaccines

Is the world living up to its climate commitments?

A Sting Exclusive: “Asia-Pacific response to COVID-19 and climate emergency must build a resilient and sustainable future”, by the United Nations Under-Secretary-General

Fed, ECB take positions to face the next global financial crisis; the Brits uncovered

The gender gap in medicine: why must it be closed?

Trump: Hostile to Europe, voids Tillerson’s “ironclad” ally pledge

Eurozone in trouble after Nicosia’s ‘no’

The future of energy is being shaped in Asia

Vaccine against Ebola: Commission grants first-ever market authorisation

Five ways individuals can help save the oceans

Why remote working doesn’t have to mean alienated employees

3 principles to reinforce digital trust in supply chains

Food safety critical to development and ending poverty: FAO deputy chief

Commission welcomes political support by Member States to improve the protection of bees

UN panel to rally global political will to tackle internal displacement crisis

Deal on digitalisation of access to justice will benefit citizens

How the digital finance revolution can drive sustainable development

Commission Vice-President Rehn exaggerates Eurozone’s growth prospects

This NASA-inspired technology converts carbon dioxide into food. Here’s how

How cities, not states, can solve the world’s biggest problems

How to stop plastic pollution at source

Working fewer hours makes you more efficient. Here’s the proof

Mexico cannot move forward ‘without addressing the shadows of the past’, says UN rights chief

Rule of law: MEPs travel to Malta to meet with government, NGOs and journalists

Tsipras imposes more austerity on insolvent Greece; plans to win new early election soon

Coronavirus: here’s what you need to know about face masks

A critical European young voice on Net Neutrality: the distance between Brussels and Washington

How to build public trust in a sustainable energy future

Syria: Urgent, concrete actions needed, to protect children too young to ‘make sense of this senseless war’

Universal Health Coverage in the EU: Are we really leaving no one behind?

This Japanese experiment shows how easily coronavirus can spread – and what you can do about it

This start-up is recycling abandoned wooden homes in Baltimore

Conflict prevention, mediation: among ‘most important tools’ to reduce human suffering, Guterres tells Security Council

A European student just sets the question of the day: What kind of education policies are missing in Europe?

MEPs approve new CO2 emissions limits for trucks

Combat against devastating effects of tobacco can only be won ‘if the UN stands united’ – UN health official

State aid: Commission approves €2.5 billion Italian scheme to support self-employed and healthcare professionals in context of coronavirus outbreak

Sudan Prime Minister survives attempted assassination

Yemen war: UN-backed talks to silence the guns due to begin in Stockholm

As Libya talks resume in Geneva, UN negotiator seeks to overcome sticking points

The health of the human being in coexistence with a transformative biosphere

This disability activist says we must offer dignity and financial inclusion rather than just braille and ramps

More Stings?

Trackbacks

  1. […] The cost of new medical technologies and drugs remains the primary cause of the high rate of medical inflation: this is why a discussion at European level with the European Federation of Pharmaceutical Industries and Associations is still open: drug pricing is at the top of the bill. […]

  2. […] Il costo di nuove tecnologie e medicinali rimane la causa principale dell’aumento dei tassi di inflazione medica: questo è il motivo per cui a livello europeo è in corso una discussione con l’Associazione Europea delle Compagnie Farmaceutiche. Il punto principale dell’agenda è sempre quello: il continuo aumento dei medicinali. […]

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s